Our study shows that complement components (C3, ASP, C4, C5, and CFB) are almost all related to the risk and severity of NAFLD, indicating that the above complement factors are expected to be potential biomarkers for clinical diagnosis and treatment of NAFLD, which is worthy of further study in the future. Here, CFB is linked to metabolic dysfunction-associated steatotic liver disease.